Diagnosis and treatment selection in elderly patients with epilepsy

Advanced Studies in Medicine

Volumn 6, Issue 3 C, 2006, Pages

  Bergey, Gregory ^a,b,c   Birnbaum, Angela K ^d   Caserta, Filissa M ^c   Ferrendelli, James A ^e   French, Jacqueline A ^f   Leppik, Ilo ^d,g  

^a Department of Neurology ^*  (United States)

^b Johns Hopkins Epilepsy Center   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g MINCEP Epilepsy Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CARBAMAZEPINE; CARDIOVASCULAR AGENT; CYTOCHROME P450 ISOENZYME; DIURETIC AGENT; DRUG METABOLITE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; LIVER ENZYME; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREGABALIN; PRIMIDONE; PROTEINASE INHIBITOR; PSYCHOTROPIC AGENT; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; ZONISAMIDE;

AGING; ATAXIA; BEHAVIOR DISORDER; BLOOD TOXICITY; CLINICAL STUDY; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; COMORBIDITY; DIAGNOSTIC IMAGING; DRUG ANTAGONISM; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; EPILEPSY; FOOD DRUG INTERACTION; HUMAN; HYPONATREMIA; IRRITABILITY; LIVER TOXICITY; NONHUMAN; ONSET AGE; OSTEOPENIA; OSTEOPOROSIS; PATIENT REFERRAL; PERIPHERAL EDEMA; POLYPHARMACY; REVIEW; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TASTE; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 33645997723     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota, 1935-1984. Epilepsia. 1993;34:453-468.
2. Annegers JF, Hauser WA, Lee JR, Rocca WA. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935-1984. Epilepsia. 1995;36:327-333.
3. US Dept of Health and Human Services, Administration on Aging. A Profile of Older Americans: 2000. Washington, DC: US Dept of Health and Human Services; 2000.
4. Garrard J, Harms S, Hardie N, et al. Antiepileptic drug use in nursing home admissions. Ann Neurol. 2003;54:75-85.
5. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005;64:1868-1873.
6. Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. 1997;27:195-204.
7. Christe W, Kramer G, Vigonius U, et al. A double-blind controlled tria: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. 1997;26:451-460.
8. Mattson RH, Cramer JA, Collins JF, et al. Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures. Neurology. 1996;47:68-76.
9. Mendez MF, Catanzaro P, Doss RC, et al. Seizures in Alzheimer's disease: clinicopathologic study. J Geriatr Psychiatry Neurol. 1994;7:230-233.
10. Mendez MF, Lim GTH. Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging. 2003;20:791-803.
11. Pedley TA, Mendiratte A, Walczak TS. Seizures and epilepsy. In: Ebersole JS, Pedley TA, eds. Current Practice of Clinical Electroencephalography. Philadelphia, Pa: Lippincott Williams & Wilkens; 2003:506-587.
12. Van Sweden B, Wauquier A, Niedermeyer E. Normal aging and transient cognitive disorders in the elderly. In: Niedermeyer E, Lopes da Silva F, eds. Electroencephalography: Basic Principles, Clinical Applications, and Related Fields. Philadelphia, Pa: Lippincott Williams & Wilkens; 1999:340-348.
13. Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. Neurology. 2004;62(5, suppl 2):S24-S29.
14. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 1985;313:145-151.
15. Mattson RH, Cramer JA, Collins JF, et al. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med. 1992;327:765-771.
16. Brodie MJ, Overstall PW, Giorgi L, et al. Multicenter, double-blind, randomized comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res. 1999;37:81-87.
17. Morrell MJ, McLean MJ, Willmore LJ, et al. Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. Seizure. 2000;9:241-248.
18. Morrell MJ, Leppik I, French J, et al. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res. 2003;54:153-161.
19. Ferrendelli JA, French J, Leppik I, et al. Use of levetiracetam in a population aged 65 years and older: a subset analysis of the KEEPER trial. Epilepsy Behav. 2003;4:702-709.
20. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62:1252-1260.
21. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62:1261-1273.
22. French JA, Schachter S. A workshop on antiepileptic drug monotherapy indications. Epilepsia. 2002;43(suppl 10):3-27.
23. Meador KJ, Loring DW, Ray PG, et al. Differential cognitive effects of carbamazepine and gabapentin. Epilepsia. 1999;40:1279-1285.
24. Meador KJ, Loring DW, Ray PG, et al. Differential cognitive and behaviora effects of carbamazepine and lamotrigine. Neurology. 2001;56:1177-1182.
25. Meador KJ, Gilliam FG, Kanner AM, Pellock JM. Cognitive and behavioral effects of antiepileptic drugs. Epilepsy Behav. 2001;2:SS1-SS17.
26. Mecarelli O, Vicenzini E, Pulitano P, et al. Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers. Ann Pharmacother. 2004;38:1816-1822.
27. Hirsch L, Weintraub D, Spencer H, et al. Predictors of cognitive side effects in patients with epilepsy. Epilepsia. 2004;45(supp 7):102.
28. Lackner TE, Cloyd JC, Thomas LW, Leppik IE. Antiepileptic drug use in nursing home residents: effect of age, gender, and comedication on patterns of use. Epilepsia. 1998;39:1083-1087.
29. Cloyd JC, Lackner TE, Leppik IE. Antiepileptics in the elderly. Pharmacoepidemiology and pharmacokinetics. Arch Fam Med. 1994;3:589-598.
30. Leppik IE, Cloyd JC. Epilepsy in the elderly. In: Levy RH, Mattson RD, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. Philadelphia, Pa: Lippincott Williams & Wilkens; 2002:149-158.
31. Birnbaum AK, Hardie NA, Conway JM, et al. Valproic acid doses, concentrations, and clearances in elderly nursing home residents. Epilepsy Res. 2004;62:157-162.
32. Birnbaum AK, Hardie NA, Conway JM, et al. Phenytoin use in elderly nursing home residents. Am J Geriatr Pharmacother. 2003;1:90-95.
33. Schachter SC, Cramer GW, Thompson GD, et al. An evaluation of antiepileptic drug therapy in nursing facilities. J Am Geriatr Soc. 1998;46:1137-1141.
34. Cloyd J. Commonly used antiepileptic drugs: age-related pharmacokinetics. In: Rowan AJ, Ramsay RE, eds. Seizures and Epilepsy in the Elderly. Boston, Mass: Butterworth-Heinemann; 1997:219-228.
35. Birnbaum A, Hardie NA, Leppik IE, et al. Variability of total phenytoin serum concentrations within elderly nursing home residents. Neurology. 2003;60:555-559.
36. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2:473-481.
37. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2:347-356.
38. Pugh MJ, Cramer J, Knoefel J, et al. Potentially inappropriate antiepileptic drugs for elderly patients with epilepsy. J Am Geriatr Soc. 2004;52:417-422.
39. Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia. 1994;35(suppl 3):S14-S19.
40. Annegers JF, Melton LJ 3rd, Sun CA, Hauser WA. Risk of age-related fractures in patients with unprovoked seizures. Epilepsia. 1989;30:348-355.
41. Roche JJ, Wenn RT, Sahota O, Moran CG. Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study. BMJ. Epub 2005 Nov 18.
42. Pack A. The association between antiepileptic drugs and bone disease. Epilepsy Curr. 2003;3:91-95.
43. Andress DL, Ozuna J, Tirschwell D, et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol. 2002;59:781-786.
44. Pack AM, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol. 2005;57:252-257.
45. Petty SJ, Paton LM, O'Brien TJ, et al. Effect of antiepileptic medication on bone mineral measures. Neurology. 2005;65:1358-1365.
46. Pack AM, Morrell MJ, Flaster E, et al. Bone mineral density changes after one year of antiepileptic drug treatment in women with epilepsy. Epilepsia. 2004;45(suppl 7):187.
47. Morganroth LP, Gidal BE, Nemire RE, et al. Occurrence of osteoporosis and risk factors in patients with epilepsy. Epilepsia. 2004;45(suppl 7):264.
48. Ensrud KE, Walczak TS, Blackwell T, et al. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology. 2004;62:2051-2057.
49. Stephen LJ, McLellan AR, Harrison JH, et al. Bone density and antiepileptic drugs: a case controlled study. Seizure. 1999;8:339-342.
50. Takahashi A, Onodera K, Kamei J, et al. Effects of chronic administration of zonisamide, an antiepileptic drug, an bone mineral density and their prevention with alfacalcidol in growing rats. J Pharmacol Sci. 2003;91:313-318.
51. Levy RH, Pitlick WH, Troupin AS, et al. Pharmacokinetics of carbamazepine in normal man. Clin Pharmacol Ther. 1975;17:657-668.
52. Carbatrol [prescribing information]. Newport, Ky: Shire US Inc; 2002.
53. Tegretol Chewable Tablets [prescribing information]. East Hanover, NJ: Novartis Pharmaceutical Corp; September 2003.
54. McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology. 1994;44(6, suppl 5):S17-S22.
55. Neurontin [prescribing information]. New York, NY: Parke-Davis Div of Pfizer Inc; 2004.
56. Birnbaum AK, Kriel RL, Im Y, Remmel RP. Relative bioavailability of lamotrigine chewable dispersible tablets administered rectally. Pharmacotherapy. 2001;21:158-162.
57. Cohen AF, Land GS, Breimer DD, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther. 1987;42:535-541.
58. Messenheimer JA. Lamotrigine. Epilepsia. 1995;36(suppl 2):S87-S94.
59. Strolin Benedetti M, Whomsley R, Nicolas JM, et al. Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur J Clin Pharmacol. 2003;59:621-630.
60. Coupez R, Straetemans R, Sehga G, et al. Levetiracetam: relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets. J Clin Pharmacol. 2003;43:1370-1376.
61. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia. 1994;35(suppl 3):S10-S13.
62. Trileptal [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; March 2004.
63. Ramsay RE. Pharmacokinetics and clinical use of parenteral phenytoin, phenobarbital, and paraldehyde. Epilepsia. 1989;30(suppl 2):S1-S3.
64. Busch JA, Strand JC, Posvar EL, et al. Pregabalin single-dose kinetics and safety/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses. Epilepsia. 1998;39(suppl 6):S58.
65. Pierce MW, Suzdak PD, Gustavson LE, et al. Tiagabine. Epilepsy Res. 1991;3(suppl):157-160.
66. Conway JM, Birnbaum AK, Kriel RL, Cloyd JC. Relative bioavailability of topiramate administered rectally. Epilepsy Res. 2003;54:91-96.
67. Doose DR, Walker SA, Gisclon LG, Nayak RK. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol. 1996;36:884-891.
68. Topamax [prescribing information]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc; June 2004.
69. Davis R, Peters DH, McTavish D. Valproic acid: a reappraisal of its pharmacologica properties and clinical efficacy in epilepsy. Drugs. 1994;47:332-372.
70. Depakote ER [prescribing information]. North Chicago, Ill: Abbott Laboratories; November 2003.
71. Depakote Sprinkle Capsules [prescribing information]. North Chicago, Ill: Abbott Laboratories; September 2003.
72. Kochak GM, Page JG, Buchanan RA, et al. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharmacol. 1998;38:166-171.
73. Zonegran [prescribing information]. San Diego, Calif: Elan Pharmaceuticals; 2004.
74. Garrard J, Cloyd J, Gross C, et al. Factors associated with antiepileptic drug use among elderly nursing home residents. J Gerontol A Biol Sci Med Sci. 2000;55:M384-M392.
75. Leppik IE. Epilepsy in the elderly. In: Contemporary Diagnosis and Managemenf of the Patient With Epilepsy. Newton, Pa: Handbooks in Health Care Co; 2000:156-163.
76. Rowan AJ. Valproate. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia, Pa: Lippincott-Raven Publishers; 1997:1599-1607.
77. Bryant AE III, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology. 1996;46:465-469.
78. Beydoun A, Sackellares JC, Shu V, et al. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Neurology. 1997;48:182-188.
79. Tettenborn B, Atefy R. Valproic acid does not cause weight gain in the elderly. Epilepsia. 2004;45(suppl 7):315.
80. Stephen LJ. Drug treatment of epilepsy in elderly people: focus on valproic acid. Drugs Aging. 2003;20:141-152.
81. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64:1134-1138.
82. Jawad S, Yuen WC, Peck AW, et al. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res. 1987;1:194-201.
83. Bergey GK. Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs. Epilepsia. 2005;46(suppl 9):161-168.
84. Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004;45:20-27.
85. French JA, Kugler AR, Robbins JL, et al. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology. 2003;60:1631-1637.
86. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(suppl 6):13-18.
87. Rosenstock J, Tuchman M, La Moreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628-638.
88. Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomized, double-blind, multicentre, placebo-controlled trial of flexible-and fixed-dose regimens. Pain. 2005;115:254-263.
89. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60:1274-1283.
90. Gidal BE, Baltes E, Otoul C, Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res. 2005;64:1-11.
91. White JR, Walczak TS, Leppik IE, et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology. 2003;61:1218-1221.
92. Cramer JA, De Rue K, Leppik IE, Kraemer G. Tolerability of levetiracetam in elderly patients with cognitive disorders, anxiety, and epilepsy. Epilepsia. 2003;44(suppl 9):16.
93. Koopmans SC, Apperson ML, Fariias ST, et al. Levetiracetam monotherapy for elderly patients with epilepsy. Epilepsia. 2003;44(suppl 9):108.
94. Werz MA, Lang P, Rienzo T. Levetiracetam therapy for epilepsy: use and tolerability in the elderly. Epilepsia. 2003;44(suppl 9):280.
95. Natale E, Vinci G, Ornella D, Ronnasa TM. Effects of levetiracetam on stroke-related seizures: an open-label trial: preliminary report. Epilepsia. 2004;45(suppl 7):310.
96. Van Parys JA, Meinardi H. Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal) on a named-patient basis. Epilepsy Res. 1994;19:79-85.
97. Kutluay E, McCague K, D'Souza J, Beydoun A. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav. 2003;4:175-180.
98. Pedersen B. Epilepsy in the elderly: the use of tiagabine. Epilepsia. 2001;42(suppl 3):52-54.
99. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003;11:722-733.
100. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003;289:1820-1825.
101. Harms SL, Eberly LE, Garrard JM, et al. Prevalence of appropriate and problematic antiepileptic combination therapy in older people in the nursing home. J Am Geriatr Soc. 2005;53:1023-1028.
102. Baulac M. Rational conversion from antiepileptic polytherapy to monotherapy. Epileptic Disord. 2003;5:125-132.
103. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314-319.
104. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia. 2001;42:1255-1260.
105. Karceski S, Morrell MJ, Carpenter D. The expert consensus guideline series: treatment of epilepsy. Epilepsy Behav. 2001;2(suppl):A1-A50.
106. Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav. 2005;(suppl 1):1-64.